Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group

It is expected that the coronavirus disease 2019 (COVID-19) pandemic will leave large deficits in the budgets of many jurisdictions. Funding for other treatments, in particular new treatments, may become more constrained than previously expected. Therefore, a robust health technology assessment (HTA...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Value Health
Autores principales: Leahy, Joy, Hickey, Conor, McConnell, David, Cassidy, Owen, Trela-Larsen, Lea, Barry, Michael, Tilson, Lesley, McCullagh, Laura
Formato: Artigo
Lenguaje:Inglês
Publicado: ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. 2020
Materias:
Themed Section: COVID-19
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7534734/
https://ncbi.nlm.nih.gov/pubmed/33127011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2020.09.003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares